Clinical Trial Update: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab [Phase 2]

View source ↗

Summary

Phase II study of a daratumumab-based combination (daratumumab, clarithromycin, pomalidomide, dexamethasone) in multiple myeloma patients previously exposed to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Pomalidomide (Pomalidomide)
• clarithromycin (clarithromycin)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING